文献速递心脑血管急症重症综合管理与镇静镇痛

磺脲类受体-1:重型创伤性脑损伤脑水肿的新型生物标志物

Sulfonylurea Receptor-1: A Novel Biomarker for Cerebral Edema in Severe Traumatic Brain Injury.
PubMed 文献 · Crit Care Med · 2017-01-01
一句话结论重型创伤性脑损伤患者脑脊液磺脲类受体-1可测及、对照组测不到,与CT脑水肿相关并先于颅内压峰值出现。

本研究收集28例重型创伤性脑损伤患者共119份脑脊液样本(12、24、48、72小时及拔除脑室外引流前),对照组15份来自正常压力脑积水患者,用酶联免疫吸附测定定量磺脲类受体-1。磺脲类受体-1在全部重型创伤性脑损伤患者中可测得(均值3.54±3.39 ng/mL,峰值7.13±6.09 ng/mL),对照组全部测不到(p<0.001)。有CT脑水肿者均值与峰值更高(4.96±1.13 ng/mL vs 2.10±0.34 ng/mL;p=0.023);91.7%的颅内高压患者磺脲类受体-1峰值与颅内压峰值之间存在时间延迟。48至72小时磺脲类受体-1下降轨迹与脑水肿改善和临床结局显著相关,多因素模型受试者工作特征曲线下面积为0.881。作者认为需要更大样本研究评估其诊断、监测及指导靶向治疗的潜力。

要点

  • 重型创伤性脑损伤患者脑脊液磺脲类受体-1全部可测得(均值3.54±3.39 ng/mL,峰值7.13±6.09 ng/mL),正常压力脑积水对照全部测不到(p<0.001)。
  • 有CT脑水肿者磺脲类受体-1均值与峰值更高:4.96±1.13 ng/mL vs 2.10±0.34 ng/mL(p=0.023)。
  • 91.7%的颅内高压患者磺脲类受体-1峰值先于颅内压峰值出现,存在时间延迟。
  • 48至72小时磺脲类受体-1下降轨迹与脑水肿改善和临床结局显著相关;多因素模型受试者工作特征曲线下面积0.881。
  • 均值/峰值磺脲类受体-1与平均/峰值颅内压、颅内压大于20 mm Hg的比例、针对水肿的治疗、去骨瓣减压术或3个月格拉斯哥结局量表均无关联。

适用人群与场景

  • 28例重型创伤性脑损伤患者,脑脊液样本在12、24、48、72小时及拔除脑室外引流前采集。
  • 对照为15例正常压力脑积水患者。

研究设计与关键结果

  • 研究类型为脑脊液生物标志物研究,共采集119份重型创伤性脑损伤患者脑脊液样本与15份正常压力脑积水对照样本,用酶联免疫吸附测定定量磺脲类受体-1。
  • 磺脲类受体-1在全部重型创伤性脑损伤患者中可测得(均值3.54±3.39 ng/mL,峰值7.13±6.09 ng/mL),对照组全部测不到(p<0.001)。
  • 有CT脑水肿者磺脲类受体-1均值与峰值更高:4.96±1.13 ng/mL vs 2.10±0.34 ng/mL(p=0.023)。
  • 91.7%的颅内高压患者磺脲类受体-1峰值与颅内压峰值之间存在时间延迟。
  • 均值/峰值磺脲类受体-1与平均/峰值颅内压、颅内压大于20 mm Hg的比例、针对水肿的治疗、去骨瓣减压术或3个月格拉斯哥结局量表均无关联。
  • 48至72小时磺脲类受体-1下降轨迹与脑水肿改善和临床结局显著相关;多因素模型受试者工作特征曲线下面积为0.881。

证据类型、等级与局限

  • 证据类型:人体脑脊液生物标志物探索性研究。
  • 局限:作者指出本研究为探索性发现,需要在更大样本研究中评估磺脲类受体-1的诊断与监测效用及其指导靶向治疗的潜力。

对床旁实践的改变

  • 作者认为,由于存在抑制磺脲类受体-1的治疗手段,需要在更大样本研究中评估脑脊液磺脲类受体-1的诊断与监测效用及其指导创伤性脑损伤及其他涉及脑水肿疾病靶向治疗的潜力。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Cerebral edema is a key poor prognosticator in traumatic brain injury. There are no biomarkers identifying patients at-risk, or guiding mechanistically-precise therapies. Sulfonylurea receptor-1-transient receptor potential cation channel M4 is upregulated only after brain injury, causing edema in animal studies. We hypothesized that sulfonylurea receptor-1 is measurable in human cerebrospinal fluid after severe traumatic brain injury and is an informative biomarker of edema and outcome.

DESIGN: A total of 119 cerebrospinal fluid samples were collected from 28 severe traumatic brain injury patients. Samples were retrieved at 12, 24, 48, 72 hours and before external ventricular drain removal. Fifteen control samples were obtained from patients with normal pressure hydrocephalus. Sulfonylurea receptor- 1 was quantified by enzyme-linked immunosorbent assay. Outcomes included CT edema, intracranial pressure measurements, therapies targeting edema, and 3-month Glasgow Outcome Scale score.

MAIN RESULTS: Sulfonylurea receptor-1 was present in all severe traumatic brain injury patients (mean = 3.54 ± 3.39 ng/mL, peak = 7.13 ± 6.09 ng/mL) but undetectable in all controls (p < 0.001). Mean and peak sulfonylurea receptor-1 was higher in patients with CT edema (4.96 ± 1.13 ng/mL vs 2.10 ± 0.34 ng/mL; p = 0.023). There was a temporal delay between peak sulfonylurea receptor-1 and peak intracranial pressure in 91.7% of patients with intracranial hypertension. There was no association between mean/peak sulfonylurea receptor-1 and mean/peak intracranial pressure, proportion of intracranial pressure greater than 20 mm Hg, use of edema-directed therapies, decompressive craniotomy, or 3-month Glasgow Outcome Scale. However, decreasing sulfonylurea receptor-1 trajectories between 48 and 72 hours were significantly associated with improved cerebral edema and clinical outcome. Area under the multivariate model receiver operating characteristic curve was 0.881.

CONCLUSIONS: This is the first report quantifying human cerebrospinal fluid sulfonylurea receptor-1. Sulfonylurea receptor-1 was detected in severe traumatic brain injury, absent in controls, correlated with CT-edema and preceded peak intracranial pressure. Sulfonylurea receptor-1 trajectories between 48 and 72 hours were associated with outcome. Because a therapy inhibiting sulfonylurea receptor-1 is available, assessing cerebrospinal fluid sulfonylurea receptor-1 in larger studies is warranted to evaluate our exploratory findings regarding its diagnostic, and monitoring utility, as well as its potential to guide targeted therapies in traumatic brain injury and other diseases involving cerebral edema.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Jha RM, Puccio AM, Chou SH, et al. Sulfonylurea Receptor-1: A Novel Biomarker for Cerebral Edema in Severe Traumatic Brain Injury. Crit Care Med. 2017. PMID: 27845954. doi:10.1097/CCM.0000000000002079

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。